ASX Health Stocks: HeraMED jumps 30pc after maternity care platform goes live at clinical trial
Health & Biotech
Health & Biotech
Link copied to
Medtech company focusing on maternity care, HeraMED (ASX:HMD), jumped over 30% this morning after announcing that its clinical trial at Gold Coast Hospital is now underway.
The clinical trial has begun for up to 90 pregnancies for a period of six to nine months; with an objective to evaluate clinical usability, patient satisfaction, and economic analysis of the HeraCARE and HeraBEAT platforms.
The company’s HeraCARE platform is a remote patient monitoring program for pregnancy and postpartum care, allowing providers to easily manage patient activity remotely through a dashboard.
The HeraBEAT platform meanwhile is said to be the only smart, medical grade foetal heart rate monitor that enables providers to accurately and safely monitor their patient’s foetal heart rates remotely.
Over the past months, the company has rigorously completed platform configuration, customisation, workflow integration and set-up before going live today.
HeraMED says the launch of this clinical trial is an important step, given that Gold Coast Hospital is an internationally recognised health institution that has embraced digital transformation.
The hospital manages more than 5,000 pregnancies per year, and is currently undertaking an ambitious digital transformation program for the health service under their Digital 2024 (D24) strategic plan.
Separately, HeraMED also announced that David Groberman has resigned as CEO and managing director with immediate effect, but will continue in a non-executive role as product strategist. A search for his replacement is currently being conducted.
Neurodegenerative diseases biotech, Alterity Therapeutics (ASX:ATH), announced it has successfully completed enrolment in its ATH434-201 Phase 2 clinical trial.
ATH434-201 is a randomised, double-blind, placebo-controlled study in patients with early-stage multiple system atrophy (MSA), conducted across the US, Europe, Australia and New Zealand.
Alterity says completing this enrolment is a significant milestone for the company.
“Due to the great clinical need and physician interest in our novel approach to address the underlying pathology of MSA, we exceeded our enrolment target,” says Alterity’s CEO, Dr David Stamler.
“With our trial now fully enrolled, study treatment will conclude in the fourth quarter of 2024, and the results from the trial will clarify the path forward for potential approval of ATH434.”
The study will evaluate the effects of ATH434 treatment on neuro-imaging and protein biomarkers to demonstrate efficacy, in addition to assessments of safety and pharmacokinetics.
Selected biomarkers, such as brain iron and aggregating α-synuclein, are said to be important contributors to MSA pathology, and are therefore appropriate targets to demonstrate drug activity.